{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:56:59Z","timestamp":1746320219458},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In patients hospitalised with COVID-19, an increased incidence of thromboembolic events, such as pulmonary embolism, deep vein thrombosis and stroke, has been reported<jats:bold>.<\/jats:bold> It is unknown whether anticoagulation can prevent these complications and improve outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A\u00a0systematic literature search was performed to answer the question: What is the effect of (prophylactic and therapeutic dose) anticoagulation therapy in COVID-19 patients on cardiovascular and thromboembolic complications and clinical outcome? Relevant outcome measures were mortality (crucial), hospital admission, length of stay, thromboembolic complications (pulmonary embolism, stroke, transient ischaemic attack), need for mechanical ventilation, acute kidney injury and use of renal replacement therapy. Medline and Embase databases were searched with relevant search terms until 17\u00a0July 2020. After systematic analysis, eight studies were included. Analysis was stratified for the start of anticoagulation before or during hospital admission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was insufficient evidence that therapeutic anticoagulation could improve the outcome in patients hospitalised with COVID-19. None of the studies demonstrated improved mortality, except for one very small Italian study. Furthermore, none of the studies showed a\u00a0positive effect of anticoagulation on other outcome measures in COVID-19, such as ICU admission, length of hospital stay, thromboembolic complications, need for mechanical ventilation, acute kidney failure or need for renal replacement therapy, except for two studies demonstrating an association between anticoagulation and a\u00a0lower incidence of pulmonary embolism. However, the level of evidence of all studies varied from \u2018low\u2019 to \u2018very low\u2019, according to the GRADE methodology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Analysis of the literature showed that there was insufficient evidence to answer our objective on the effect of anticoagulation on outcome in COVID-19 patients, especially due to the low scientific quality of the described studies. Randomised controlled studies are needed to answer this question.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-021-01574-7","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T12:34:48Z","timestamp":1618576488000},"page":"35-44","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of anticoagulant therapy in COVID-19 patients"],"prefix":"10.1007","volume":"29","author":[{"given":"R. G.","family":"Tieleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Belfroid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hoogervorst-Schilp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Schalkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. W.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Siebelink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"1574_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok\u00a0FA, Kruip\u00a0MJHA, van der Meer\u00a0NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145\u20137.","journal-title":"Thromb Res"},{"key":"1574_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok\u00a0FA, Kruip\u00a0MJHA, van der Meer\u00a0NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148\u201350.","journal-title":"Thromb Res"},{"key":"1574_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","volume":"46","author":"J Helms","year":"2020","unstructured":"Helms\u00a0J, Tacquard\u00a0C, Severac\u00a0F, et al. High risk of thrombosis in patients with severe SARS-CoV\u20112 infection: a\u00a0multicenter prospective cohort study. Intensive Care Med. 2020;46:1089\u201398.","journal-title":"Intensive Care Med"},{"key":"1574_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","volume":"191","author":"C Lodigiani","year":"2020","unstructured":"Lodigiani\u00a0C, Iapichino\u00a0G, Carenzo\u00a0L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9\u201314.","journal-title":"Thromb Res"},{"key":"1574_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/jama.2020.13372","volume":"324","author":"S Bilaloglu","year":"2020","unstructured":"Bilaloglu\u00a0S, Aphinyanaphongs\u00a0Y, Jones\u00a0S, Iturrate\u00a0E, Hochman\u00a0J, Berger\u00a0JS. Thrombosis in hospitalized patients with COVID-19 in a\u00a0new York city health system. JAMA. 2020;324:799\u2013801.","journal-title":"JAMA"},{"key":"1574_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/jth.14888","volume":"18","author":"S Middeldorp","year":"2020","unstructured":"Middeldorp\u00a0S, Coppens\u00a0M, van Haaps\u00a0TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J\u00a0Thromb Haemost. 2020;18:1995\u20132002.","journal-title":"J Thromb Haemost"},{"key":"1574_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jth.14817","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang\u00a0N, Bai\u00a0H, Chen\u00a0X, Gong\u00a0J, Li\u00a0D, Sun\u00a0Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J\u00a0Thromb Haemost. 2020;18:1094\u20139.","journal-title":"J Thromb Haemost"},{"key":"1574_CR8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood.2020006941","volume":"136","author":"D Tremblay","year":"2020","unstructured":"Tremblay\u00a0D, van Gerwen\u00a0M, Alsen\u00a0M, et al. Impact of anticoagulation prior to COVID-19 infection: a\u00a0propensity score-matched cohort study. Blood. 2020;136:144\u20137.","journal-title":"Blood"},{"key":"1574_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104965","author":"V Russo","year":"2020","unstructured":"Russo\u00a0V, Di Maio\u00a0M, Attena\u00a0E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res. 2020; https:\/\/doi.org\/10.1016\/j.phrs.2020.104965.","journal-title":"Pharmacol Res"},{"key":"1574_CR10","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1111\/bjh.16968","volume":"190","author":"H Sivaloganathan","year":"2020","unstructured":"Sivaloganathan\u00a0H, Ladikou\u00a0EE, Chevassut\u00a0T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematology. 2020;190:e192\u2013e5.","journal-title":"Br J Haematology"},{"key":"1574_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejim.2020.06.006","volume":"77","author":"R Rossi","year":"2020","unstructured":"Rossi\u00a0R, Coppi\u00a0F, Talarico\u00a0M, Boriani\u00a0G. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Eur J Intern Med. 2020;77:158\u201360.","journal-title":"Eur J Intern Med"},{"key":"1574_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","volume":"76","author":"I Paranjpe","year":"2020","unstructured":"Paranjpe\u00a0I, Fuster\u00a0V, Lala\u00a0A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J\u00a0Am Coll Cardiol. 2020;76:122\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"1574_CR13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/jth.14869","volume":"18","author":"J-F Llitjos","year":"2020","unstructured":"Llitjos\u00a0J\u2011F, Leclerc\u00a0M, Chochois\u00a0C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J\u00a0Thromb Haemost. 2020;18:1743\u20136.","journal-title":"J Thromb Haemost"},{"key":"1574_CR14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/eurheartj\/ehaa280","volume":"41","author":"M Linschoten","year":"2020","unstructured":"Linschoten\u00a0M, Asselbergs\u00a0FW. CAPACITY-COVID: a\u00a0European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. Eur Heart\u00a0J. 2020;41:1795\u20136.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01574-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-021-01574-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01574-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:32:19Z","timestamp":1619094739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-021-01574-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":14,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1007\/s12471-021-01574-7","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"31 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G.\u00a0Tieleman, F.A.\u00a0Klok, E.\u00a0Belfroid, J.\u00a0Hoogervorst-Schilp, I.\u00a0Schalkers, C.W.\u00a0Jansen and H.\u00a0J.\u00a0Siebelink declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}